BGPT: Best Evidence: Extract High Level RCT Data for BRAF and MSI trials

Explore by Goal

Quick Explanation Copied

Your provided evidence bundle does **not contain RCTs** for **BRAF** or **MSI** trials; it is dominated by **preclinical, diagnostic, and observational/small cohort** material (e.g., murine BRAF vaccine/response, BRAF mutation detection in leukemia/lymphomas, and non-RCT retrospective sequencing in melanoma). Therefore, I can’t truthfully “extract high-level RCT data” for BRAF/MSI from what you supplied—only audit what’s actually present and flag the gap.

Long Explanation

Evidence Audit: “Best Evidence: Extract High Level RCT Data for BRAF and MSI trials”

Date context: April 28, 2026. Your supplied “research data” items do not include randomized controlled trials (RCTs) for either BRAF or MSI—so “extract RCT endpoints” can’t be performed honestly from this bundle.

1) What’s actually in your bundle (RCT presence check)

Based on the titles/one-sentence summaries and provided metadata, the items fall into: preclinical animal/cell studies (e.g., murine BRAF vaccine; metabolism + BRAF inhibition in cell lines; BRAF-inhibitor–accelerated tumors in a mouse model), diagnostic/genetic testing (BRAF mutation detection, BRAF mutation prevalence in tumor types), and retrospective clinical sequencing (not RCT). Example: the melanoma sequencing item explicitly states it is retrospective with small n=25.

2) Category breakdown (from provided items only)

I bucketed each provided DOI-item by study type using only the text you supplied (titles/summaries and metadata). This is an audit of your bundle, not of the full literature.

Preclinical examples: murine BRAF peptide vaccine and COX-2 inhibition in a mouse skin carcinogenesis model . Diagnostic/genomic: BRAF exon screening in HCL and HRM+sequencing for BRAF V600E in HCL-related disorders . Systematic review: BRAF status relevance in glial/glioneuronal tumors . Retrospective clinical: sequential immunotherapy vs BRAF inhibitors in BRAF-mutant advanced melanoma . Mechanistic functional resistance: secondary BRAF mutation resistance study described in supplementary material .

3) Table: what each item is (and why it can’t supply RCT endpoints)

DOI	Type (from provided metadata)	Population/Model (as given)	Key limitation for RCT extraction
10.1007/s00262-017-2079-7	Preclinical (murine)	Female C57BL/6 mice; BPD6 syngeneic model	No human randomization; immune/tumor endpoints in mice
10.1111/bjh.12735	Diagnostic/genomic (human specimens)	Hairy cell leukemia cases lacking V600E (n=24 HCL cases)	Assay prevalence/diagnostics; no treatment randomization
10.1158/2159-8290.22532320.v1	Mechanistic/resistance (supplementary)	Patient tumor samples pre/post; functional assays (NIH-3T3)	Resistance mechanism, not randomized comparative efficacy
10.1016/j.jocn.2019.05.014	Systematic review	52 studies; total 512 patients across tumor types	Synthesis of heterogeneous observational evidence; not RCT data extraction
10.2217/pme.13.27	Narrative/diagnostic review-like evidence (no sample sizes provided)	Brain tumor diagnostic discussion	Doesn’t provide RCT endpoints; sample sizes not specified in supplied metadata
10.3324/haematol.2011.054874	Diagnostic performance study (human)	HCL / related disorders; 51 patients (HCL) + 34 patients (other)	Assay sensitivity/LOD; feasibility; no randomized therapy comparison
10.1097/01.cmr.0000222600.73179.f3	Prevalence/genomics (human)	Melanoma (n=82) + benign nevi (n=51)	Mutation frequencies, not intervention randomization
10.1016/j.eplepsyres.2016.08.028	Human cohort biomarkers	Dysembryoplastic neuroepithelial tumors (DNTs), n=64	Marker frequency (BRAF V600E, copy-number gain); no RCT endpoints
10.1038/srep42604	Preclinical cell biology	Panel of BRAF-mutant melanoma cell lines (n=10 for metabolic profiling)	Correlation of glycolysis phenotype with drug sensitivity in vitro
10.1007/s12094-016-1514-0	Retrospective clinical study (non-RCT)	BRAF V600 mutant advanced melanoma; n=25 total	Retrospective sequence comparison; no randomization

4) Why the requested “high-level RCT extraction” can’t be completed from this dataset

No MSI RCT material is present in the supplied items (none of the listed DOIs/summaries mention MSI as a trial eligibility biomarker or an MSI-targeted randomized strategy). Hence, there’s nothing to extract for MSI trials from the provided bundle.
For BRAF: several items are mechanistic/preclinical or diagnostics, which cannot supply human RCT endpoints such as randomized objective response, progression-free survival, overall survival, and adverse event rates under assigned arms.
Even the clinical item provided is retrospective (small n; non-randomized comparison).

What would change this conclusion? If you provide actual RCT papers/trial reports (or at least trial identifiers like NCT numbers + full-text extracts), I can then extract high-level RCT data (arm sizes, inclusion criteria, endpoints, effect sizes, and CIs) and visualize them.

5) Next-step BGPT actions (so we can get real RCTs)

If you want, paste/attach the actual RCT PDFs or provide trial IDs; I can then create RCT arm-by-arm tables and effect-size plots grounded in the full text.

Required: run a Science AI Agent to complete the extraction

Your supplied bundle is insufficient for RCT extraction; the agent can search BGPT’s raw-paper database for true randomized BRAF and MSI trials and then extract high-level RCT data.

Scientific humility note: This response is constrained to the items you pasted. I did not invent or import RCTs that aren’t in your provided data.

Feedback:

Updated: April 28, 2026

Top Data Sources Export MCP

1. This study demonstrates that a BRAF peptide vaccine delivered via lipid-coated calcium phosphate nanoparticles effectively induces a robust immune response and inhibits tumor growth in a murine model of BRAF-mutant melanoma. [2017]

8QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

2. This study identifies novel BRAF mutations in exon 11 of hairy cell leukaemia (HCL) cases that lack the common BRAF V600E mutation, suggesting the need for alternative mutation screening in diagnostic settings. [2014]

8QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

3. This study investigates a secondary mutation in BRAF that confers resistance to RAF inhibition in a BRAF V600E-mutant brain tumor, highlighting the implications for treatment strategies. [2023]

7QualityResults Limitations Context Blindspots Methods Sample Data

↗ Paper Review ↗ Full Paper

4. This systematic review investigates the clinical relevance of BRAF status in glial and glioneuronal tumors, revealing that KIAA1549-BRAF fusion is predominantly associated with pilocytic astrocytoma and that BRAF mutations are more common in older patients, with specific imaging features linked to these genetic alterations. [2019]

7QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

5. This study investigates the diagnostic and clinical relevance of BRAF status determination in brain tumors, particularly focusing on the implications of BRAF mutations and fusions in gliomas and their potential therapeutic targets. [2013]

7QualityResults Limitations Context Blindspots Methods Sample

↗ Paper Review ↗ Full Paper

Key Insight

Your dataset is rich in biology and diagnostics for BRAF, but it’s structurally misaligned with the requested evidence goal (MSI/BRAF RCT extraction), meaning the biggest scientific failure mode here is category mismatch rather than weak results.

Keep Exploring

Which specific BRAF RCTs (phase, population, comparators) should be prioritized for endpoint extraction if the target audience is MSI-dMMR overlap research?

What is the minimal ‘RCT evidence schema’ (required fields) needed to prevent category mismatch in automated evidence extraction?

Hypothesis Graveyard

A plausible but now rejected idea: “The bundle contains enough RCT-like efficacy data.” Rejected because none of the listed items describe randomized human trial arms/endpoints in the supplied metadata.

Another rejected idea: “MSI trial endpoints can be inferred from BRAF/diagnostic papers.” Rejected because MSI is not represented in the supplied items.

Potential Experiments

Create an evidence-type filter: build a pipeline that only admits RCTs (randomization + control arms + prespecified endpoints) before any endpoint synthesis; validate that it prevents the category mismatch seen here.

Perform an evidence completeness audit: quantify how many unique MSI RCTs exist in BGPT for a query set, then compare the returned coverage against the requested endpoint extraction schema (arm size, OS/PFS/ORR, AEs).

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I may over-weight the provided bundle’s study-type metadata and underweight the possibility that hidden RCT content exists inside files not included here.

Stay current without chasing every paper.

Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Explanation Copied

Long Explanation

Evidence Audit: “Best Evidence: Extract High Level RCT Data for BRAF and MSI trials”

1) What’s actually in your bundle (RCT presence check)

2) Category breakdown (from provided items only)

3) Table: what each item is (and why it can’t supply RCT endpoints)

4) Why the requested “high-level RCT extraction” can’t be completed from this dataset

5) Next-step BGPT actions (so we can get real RCTs)

Required: run a Science AI Agent to complete the extraction

Top Data Sources Export MCP

1. This study demonstrates that a BRAF peptide vaccine delivered via lipid-coated calcium phosphate nanoparticles effectively induces a robust immune response and inhibits tumor growth in a murine model of BRAF-mutant melanoma. [2017]

2. This study identifies novel BRAF mutations in exon 11 of hairy cell leukaemia (HCL) cases that lack the common BRAF V600E mutation, suggesting the need for alternative mutation screening in diagnostic settings. [2014]

3. This study investigates a secondary mutation in BRAF that confers resistance to RAF inhibition in a BRAF V600E-mutant brain tumor, highlighting the implications for treatment strategies. [2023]

5. This study investigates the diagnostic and clinical relevance of BRAF status determination in brain tumors, particularly focusing on the implications of BRAF mutations and fusions in gliomas and their potential therapeutic targets. [2013]

7. This study investigates the prevalence of BRAF and NRAS mutations in melanoma and benign melanocytic nevi, revealing that BRAF mutations are common in nevi and superficial spreading melanomas, while NRAS mutations are rare and mutually exclusive with BRAF mutations. [2006]

9. This study investigates the relationship between tumor metabolic phenotype and sensitivity to BRAF inhibitors in BRAF-mutated melanoma, demonstrating that increased reliance on glycolysis enhances therapeutic response to the BRAF inhibitor PLX4720. [2017]

12. This study demonstrates that COX-2 inhibition using celecoxib significantly prevents the development of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors in a mouse model, suggesting a potential chemopreventive strategy for patients undergoing BRAF inhibitor therapy. [2013]

Ask a Follow-Up

Key Insight

Your dataset is rich in biology and diagnostics for BRAF, but it’s structurally misaligned with the requested evidence goal (MSI/BRAF RCT extraction), meaning the biggest scientific failure mode here is category mismatch rather than weak results.

Keep Exploring

Which specific BRAF RCTs (phase, population, comparators) should be prioritized for endpoint extraction if the target audience is MSI-dMMR overlap research?

What is the minimal ‘RCT evidence schema’ (required fields) needed to prevent category mismatch in automated evidence extraction?

Hypothesis Graveyard

A plausible but now rejected idea: “The bundle contains enough RCT-like efficacy data.” Rejected because none of the listed items describe randomized human trial arms/endpoints in the supplied metadata.

Another rejected idea: “MSI trial endpoints can be inferred from BRAF/diagnostic papers.” Rejected because MSI is not represented in the supplied items.

Potential Experiments

Create an evidence-type filter: build a pipeline that only admits RCTs (randomization + control arms + prespecified endpoints) before any endpoint synthesis; validate that it prevents the category mismatch seen here.

Perform an evidence completeness audit: quantify how many unique MSI RCTs exist in BGPT for a query set, then compare the returned coverage against the requested endpoint extraction schema (arm size, OS/PFS/ORR, AEs).

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I may over-weight the provided bundle’s study-type metadata and underweight the possibility that hidden RCT content exists inside files not included here.

Stay current without chasing every paper.

My BGPT

Trending

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Explanation Copied

Long Explanation

Evidence Audit: “Best Evidence: Extract High Level RCT Data for BRAF and MSI trials”

1) What’s actually in your bundle (RCT presence check)

2) Category breakdown (from provided items only)

3) Table: what each item is (and why it can’t supply RCT endpoints)

4) Why the requested “high-level RCT extraction” can’t be completed from this dataset

5) Next-step BGPT actions (so we can get real RCTs)

Required: run a Science AI Agent to complete the extraction

Top Data Sources ExportMCP

1. This study demonstrates that a BRAF peptide vaccine delivered via lipid-coated calcium phosphate nanoparticles effectively induces a robust immune response and inhibits tumor growth in a murine model of BRAF-mutant melanoma. [2017]

2. This study identifies novel BRAF mutations in exon 11 of hairy cell leukaemia (HCL) cases that lack the common BRAF V600E mutation, suggesting the need for alternative mutation screening in diagnostic settings. [2014]

3. This study investigates a secondary mutation in BRAF that confers resistance to RAF inhibition in a BRAF V600E-mutant brain tumor, highlighting the implications for treatment strategies. [2023]

5. This study investigates the diagnostic and clinical relevance of BRAF status determination in brain tumors, particularly focusing on the implications of BRAF mutations and fusions in gliomas and their potential therapeutic targets. [2013]

7. This study investigates the prevalence of BRAF and NRAS mutations in melanoma and benign melanocytic nevi, revealing that BRAF mutations are common in nevi and superficial spreading melanomas, while NRAS mutations are rare and mutually exclusive with BRAF mutations. [2006]

9. This study investigates the relationship between tumor metabolic phenotype and sensitivity to BRAF inhibitors in BRAF-mutated melanoma, demonstrating that increased reliance on glycolysis enhances therapeutic response to the BRAF inhibitor PLX4720. [2017]

12. This study demonstrates that COX-2 inhibition using celecoxib significantly prevents the development of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors in a mouse model, suggesting a potential chemopreventive strategy for patients undergoing BRAF inhibitor therapy. [2013]

Ask a Follow-Up

Key Insight

Your dataset is rich in biology and diagnostics for BRAF, but it’s structurally misaligned with the requested evidence goal (MSI/BRAF RCT extraction), meaning the biggest scientific failure mode here is category mismatch rather than weak results.

Keep Exploring

Which specific BRAF RCTs (phase, population, comparators) should be prioritized for endpoint extraction if the target audience is MSI-dMMR overlap research?

What is the minimal ‘RCT evidence schema’ (required fields) needed to prevent category mismatch in automated evidence extraction?

Hypothesis Graveyard

A plausible but now rejected idea: “The bundle contains enough RCT-like efficacy data.” Rejected because none of the listed items describe randomized human trial arms/endpoints in the supplied metadata.

Another rejected idea: “MSI trial endpoints can be inferred from BRAF/diagnostic papers.” Rejected because MSI is not represented in the supplied items.

Potential Experiments

Create an evidence-type filter: build a pipeline that only admits RCTs (randomization + control arms + prespecified endpoints) before any endpoint synthesis; validate that it prevents the category mismatch seen here.

Perform an evidence completeness audit: quantify how many unique MSI RCTs exist in BGPT for a query set, then compare the returned coverage against the requested endpoint extraction schema (arm size, OS/PFS/ORR, AEs).

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I may over-weight the provided bundle’s study-type metadata and underweight the possibility that hidden RCT content exists inside files not included here.

Stay current without chasing every paper.

My BGPT

Trending

Top Data Sources Export MCP